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Summary 
The small molecule CADA was shown to down-modulate the expression of human CD4 
in a signal peptide-dependent way, through inhibition of its co-translational translocation 
across the ER membrane. Previous studies characterizing general glycoprotein levels 
and the expression of 14 different cell surface receptors showed selectivity of CADA for 
human CD4. Here, a PowerBlot western array was used as a screen to analyze the 
proteome of CADA-treated SUP-T1 human CD4+ T lymphocytes. This high-throughput 
monoclonal antibody panel-based immunoblotting assay of cellular signaling proteins 
revealed that only a small subset of the 444 detected proteins was differentially expressed 
after treatment with CADA. Validation of these proteomic data with optimized immunoblot 
analysis confirmed the CADA-induced change in expression of the cell cycle progression 
regulator pRb2 and the transcription factor c-Jun. However, the up-regulation of pRb2 or 
down-modulation of c-Jun by CADA had no impact on cell cycle transition. Also, the 
reduced protein level of human CD4 did not inhibit T cell receptor signaling. Interestingly, 
the signal peptide-containing membrane protein sortilin was identified as a new substrate 
for CADA. Both cellular expression and in vitro co-translational translocation of sortilin 
were significantly reduced by CADA, although to a lesser extent as compared to human 
CD4. Our data demonstrate that a small signal peptide-binding drug is able to down-
modulate the expression of human CD4 and sortilin, apparently with low impact on the 
cellular proteome. 
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Introduction 
According to the World Health Organization, the human immunodeficiency virus (HIV) 
has infected almost 78 million people worldwide since its discovery in the early eighties, 
resulting in the death of more than 34 million people. Currently, 25 different FDA-approved 
anti-HIV drugs are in clinical use, turning HIV and acquired immune deficiency syndrome 
into a more chronic disease, yet not curable. In addition, HIV can develop resistance to 
almost all classes of antiretroviral drugs, making the development of new therapies and 
anti-HIV drugs an ongoing challenge (1). 
The synthetic small molecule cyclotriazadisulfonamide (CADA; Fig. 1A) was identified 
as a novel anti-HIV agent in an earlier screening program (2). This compound prevents 
viral entry of different HIV-1 lab strains and clinical isolates into T lymphocytes but does 
not interact with viral components. Instead, CADA down-modulates the cell surface 
expression of the human CD4 (hCD4) glycoprotein (2-7), known as the main receptor for 
HIV entry (8). Moreover, a strict correlation between the hCD4 down-modulating activity 
and anti-HIV potency of CADA-derived compounds has been demonstrated (3). 
Recently, the mechanism of action of CADA has been unraveled: the drug selectively 
binds to the signal peptide (SP) of the hCD4 pre-protein, and prevents it from being 
translocated into the lumen of the endoplasmic reticulum (ER) (9). Signal peptides (also 
called signal sequences) are located at the amino-terminus of pre-proteins destined for 
secretion or plasma membrane insertion. They are crucial for targeting those proteins to 
the secretory pathway (10). Despite their distinct functional role, signal peptides are 
diverse and lack a conserved primary sequence (11). 
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Our previous studies showed that hCD4 protein biogenesis is inhibited by CADA in a 
signal peptide-dependent way, resulting in a significant down-modulation of cell surface 
hCD4 levels. They also suggested selectivity of CADA for hCD4 as the compound does 
not affect cell surface expression of 14 different T lymphocyte receptors nor CD4 from 
non-primate species. In addition, cell lysate analysis with concanavalin A agarose beads 
demonstrated no changes in the expression of glycosylated membrane proteins other 
than hCD4 (2, 9). 
Here, we employed a PowerBlotTM Western Array to identify potential other substrates 
of CADA (besides hCD4) in human CD4+ T lymphocytes. This high-throughput 
immunoblotting technology simultaneously evaluates changes in the expression and 
post-translational modification of several hundreds of cellular signaling proteins in total 
cell extracts from treated and untreated cells. Analysis identified a small subset of the 444 
detected proteins as being affected by CADA. Of these, the signal peptide-containing 
membrane protein sortilin was validated as a new substrate of CADA. 
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Materials and methods 
Compounds and antibodies 
Cyclotriazadisulfonamide hydrochloride was dissolved in dimethyl sulfoxide (DMSO) to 
obtain a 10 mM stock solution for use in cell culture. FITC-labeled anti-human CD4 [clone 
SK3] (BioLegend), Phycoerythrin (PE)-labeled anti-human CD4 [clone SK3] (BioLegend) 
and Allophycocyanin-labeled anti-human CD4 [clone SK3] (BD Biosciences) monoclonal 
antibodies were used for flow cytometry. Anti-CD3 [clone OKT3] from eBioscience and 
goat anti-mouse IgG [Poly4053] from BioLegend were used for TCR activation. Western 
blot antibodies were purchased from (i) BD Biosciences: anti-human CD4 [clone SK3], 
GAP1m [clone 15], p19 skp1 [clone 52], sequestome-1/p62 Lck ligand [clone 3], FUS/TLS 
[clone 15], XRCC4 [clone 4], p56 Lck [clone 28], Rb2 [clone 10], clathrin [clone 23]; (ii) 
Thermo Scientific: anti-c-Jun [clone 5B1], STAT1 [clone 15H3], cyclin D3 [clone DCS-22]; 
(iii) R&D Systems: anti-sortilin [clone 334708]; (iv) Abcam: anti-sortilin [clone EPR15010]; 
(v) Abnova: anti-ASAP-1 [clone 2G7]; (vi) Dako: HRP-labeled goat anti-mouse 
immunoglobulins, HRP-labeled swine anti-rabbit immunoglobulins; and (vii) Cell 
Signaling Technologies: polyclonal anti-LAT, pLAT (Tyr191), pZAP-70 (Tyr493), 
monoclonal anti ZAP-70 [clone D1C10E], pZAP-70 (Tyr319) [clone 65E4], HRP-labeled 
goat anti-rabbit immunoglobulins. 
Cell culture 
Cells were obtained from the American Type Culture Collection, and were maintained at 
37 °C with 5% CO2. SUP-T1 and Jurkat lymphoma cells were cultured in Roswell Park 
Memorial Institute 1640 medium (Life Technologies) supplemented with 10% fetal bovine 
serum (HyClone, GE Lifesciences) and 2 mM L-glutamine (Life Technologies). HEK293T 
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cells were cultured in Dulbecco’s Modified Eagle Medium (Life Technologies) 
supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate (Life Technologies) 
and 0.075% sodium bicarbonate (Life Technologies). 
Plasmids 
Plasmid pGEMBP1 encoding bovine preprolactin (pPL) has been described previously 
(12). Inverse PCR based site-directed mutagenesis (13) was used to replace the pPL 
signal peptide in pGEMBP1 with the sortilin signal peptide (residues 1-33). The hCD4/pPL 
chimeric construct and the pcDNA3 expression vector encoding hCD4 have been 
described (9). The pCMV6-AC-GFP vector containing SORT1 cDNA was obtained from 
OriGene Technologies. 
Flow cytometry 
SUP-T1 cells were seeded at 1.5×105 cells/ml in Corning Costar 24-well plates, 
supplemented with the indicated amount of CADA or 0.1% DMSO as a control and were 
incubated for 72 h. Cells were then washed in PBS and stained with anti-hCD4-FITC. 
Samples were stored in PBS containing 1% formaldehyde before acquisition on a 
FACSCalibur flow cytometer (BD Biosciences) with BD CellQuest software v3.3. A FACS 
Canto II flow cytometer (Becton Dickinson) with BD FACSDiva 8.0.1 software was used 
for cell cycle analysis and to quantify expression of hCD4 (stained with PE-labeled anti-
hCD4) on SUP-T1 and Jurkat cells after T cell receptor activation. Transfected HEK293T 
cells were collected 48 h after transfection. Sortilin expression was determined through 
GFP fluorescence and hCD4 expression was measured with anti-hCD4-APC on a 
FACSCanto II flow cytometer. All flow cytometric data were analyzed in FlowJo v10.1.  
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BD PowerBlotTM Western Array 
Cells were left untreated or were treated with 16 µM CADA for 72 h before lysis in boiling 
lysis buffer (10 mM tris(hydroxymethyl)aminomethane (Tris)∙HCl pH 7.4, 1 mM sodium 
orthovanadate, 1% sodium dodecyl sulfate (SDS)). Lysates were homogenized by 
sonication and total protein concentration was determined with the bicinchoninic acid 
protein assay (Pierce) before freezing at -80 °C for shipping to BD Biosciences on dry ice. 
Protein (200 µg) was loaded in one big lane across the entire width of a 130 × 100 × 0.5 
mm, 4-15% SDS polyacrylamide gel. Electrophoresis was performed at 150 V for 90 min 
and the proteins were wet-transferred to Immobilon-P membranes (Millipore). After 
transfer, the membranes were dried and re-wet in methanol before incubation with 
blocking buffer (LI-COR) for 1 h. A manifold that isolates 41 narrow channels was clamped 
to the membrane and a complex antibody cocktail was added to each channel. In this 
way, a panel of 1000 different monoclonal antibodies was hybridized across 5 identical 
membranes. After 1 h incubation, the blot was removed from the manifold, washed and 
hybridized for 30 min with goat anti-mouse conjugated to Alexa Fluor 680 (Molecular 
Probes). Then, the membrane was washed, dried and scanned at 700 nm on an Odyssey 
Infrared Imaging System (LI-COR). Lanes 40 or 41 were incubated with an antibody 
cocktail detecting molecular weight standards. Signal intensities from each spot were 
quantified, normalized and expressed as a ratio to determine increase or decrease in 
protein expression. Normalization was done by multiplying the raw signal intensity of a 
spot by 1×106 and dividing by the total signal intensity of all valid spots on an image. 
Triplicate blots for control and treated were compared in a 3x3 matrix, e.g. control run 1 
was compared to treated run 1, 2 and 3, control run 2 was compared to treated run 1, 2 
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and 3, etc. The resulting 9 comparisons were used for the determination of a semi-
quantitative fold change value. Signals with a greater than 1.25 fold change were 
classified based on the size of change, signal quality and visual inspection of signal spots 
by a technician. 10 confidence levels (CL) were used for classification (Table S1), with 10 
being the highest level of confidence. 
Bioinformatic tools 
To identify proteins with a signal peptide or uncleaved signal anchor sequence (SAS), we 
analyzed protein reference sequences obtained from the UniProt database 
(http://www.uniprot.org/uniprot/) with SignalP v4.1 
(http://www.cbs.dtu.dk/services/SignalP/), TargetP v1.1 
(http://www.cbs.dtu.dk/services/TargetP/), TMHMM v.2.0 
(http://www.cbs.dtu.dk/services/TMHMM/) (14) and Phobius (http://phobius.cgb.ki.se/) 
(15). Results were validated against the curated UniProtKB database annotation. 
Classical Western Blot 
SUP-T1 cells were seeded at 1.5×105 cells/ml and treated with 10 µM CADA or 0.1% 
DMSO as a control for 72 h. To detect hCD4, the cells were lysed in ice-cold NP-40 buffer 
(50 mM Tris∙HCl pH 8.0, 150 mM NaCl, 1% NP-40) supplemented with protease inhibitor 
cocktail (Roche) and centrifuged at 14.000 × g for 10 min to pellet nuclei and debris. All 
other proteins were extracted by lysing cells in ice-cold radioimmunoprecipitation assay 
buffer (50 mM Tris∙HCl pH 8.0, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.5% 
SDS) and homogenized by passing the samples ten times through a 26-gauge needle. 
Total protein concentration of all samples was determined with the bicinchoninic acid 
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protein assay (Pierce). For SDS gel electrophoresis, samples were boiled in reducing 2X 
Laemmli sample buffer (120 mM Tris∙HCl pH 6.8, 4% SDS, 20% glycerol, 100 mM 
dithiothreitol, 0.02% bromophenol blue). Non-reducing buffer lacking dithiothreitol was 
used for the hCD4 lysates. Equal protein amounts (~8 µg per lane, equivalent to the 
PowerBlot concentration) were separated on 4-12% Criterion XT Bis-Tris gels (Bio-Rad) 
using MES buffer (Bio-Rad). After electrophoresis, gels were blotted onto PVDF 
membranes using the Trans-Blot Turbo transfer system (Bio-Rad). Membranes were 
blocked for 1 h with 5% non-fat dried milk in TBST (20 mM Tris∙HCl pH 7.6, 137 mM NaCl, 
0.05% Tween-20). After overnight incubation of the primary antibodies at 4 °C, 
membranes were washed and incubated with the secondary antibodies. SuperSignal 
West Femto chemiluminescence reagent (Pierce) was used for detection in conjunction 
with a ChemiDoc MP system (Bio-Rad), and signal intensities were quantified with Image 
Lab software v5.0 (Bio-Rad). Differences in protein concentration between each lane 
were compensated by normalizing for the clathrin heavy chain signal. 
T cell receptor stimulation 
Jurkat or SUP-T1 cells were seeded in RPMI1640 medium supplemented with 10% FBS, 
2 mM L-glutamine and 10 mM CADA or 0.1% DMSO as a control and incubated for 24 
hours at 37°C, 5% CO2. The cells were washed and placed on ice for binding of mouse 
anti-CD3 and goat anti-mouse IgG antibodies. TCR signaling was then activated by 
placing the cells in a 37°C water bath for 2 minutes, followed by immediate cooling and 
lysis in NP-40 buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40, 0.5 mM PMSF) 
supplemented with cOmplete protease inhibitor cocktail (Roche) and phosphatase 
inhibitor cocktail (Active Motif). Lysates were cleared by centrifugation (15 min at 
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17,000×g and 4°C) and the supernatant was boiled in 2X reducing Laemmli sample buffer 
for SDS-PAGE and Western Blot analysis (described above). 
Cell cycle analysis 
SUP-T1 cells were seeded in Corning Costar 24-well plates at 1.5×105 cells/mL, 
supplemented with 0.1 nM to 1 μM palbociclib (PD-0332991, Sigma), 10 μM CADA or 
0.1% DMSO as a control and incubated for 48 hours at 37°C with 5% CO2. Next, cells 
were washed with ice-cold PBS and fixed in ice-cold methanol. Cells were then washed 
again and stained with 10 μg/ml propidium iodide and 50 μg/ml RNase A for flow 
cytometric analysis. 
Cell transfection 
HEK293T cells were plated at 3×105 cells/ml in Corning Costar 24-well plates, and were 
transfected with human SORT1 and/or hCD4 plasmid cDNA 24 h after plating. 
Transfections were carried out by making use of Lipofectamine 2000 transfection reagent 
(Invitrogen). After 6 h, indicated amounts of CADA or 0.1% DMSO were added, and cells 
were collected for flow cytometric analysis 48 h after transfection.  
Cell-free in vitro translation 
Full-length mRNAs were transcribed in vitro from NheI linearized pGEM plasmids using 
T7 RNA polymerase (RiboMAX system, Promega) and translated in rabbit reticulocyte 
lysate (Promega) in the presence of L-[35S]-methionine (Perkin Elmer). Translations were 
performed at 25 °C for 45 min in the presence or absence of sheep pancreatic 
microsomes. The proteinase K (Roche) digestion was performed on ice for 30 min and 
quenched with phenylmethylsulfonyl fluoride (Thermo Fisher Scientific). 10 µL reaction 
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mixtures were diluted with 300 µL low-salt buffer (80 mM KOAc, 2 mM Mg(OAc)2, 50 mM 
HEPES pH 7.6) and radiolabeled proteins were centrifuged for 10 minutes at 21,382×g 
and 4°C (Hettich 200R centrifuge with 2424-B rotor). Supernatant was removed and the 
pellet was resuspended in 30 µL Laemmli sample buffer. The radiolabeled proteins were 
then separated by SDS-PAGE, dried and analyzed with a Cyclone Plus phosphor imager 
system (Perkin Elmer). 
Experimental design and statistical rationale 
For each flow cytometric sample, 5000 to 20000 cells were analyzed, and at least 2 
biological replicates were performed, as indicated in the figure legends. The BD 
PowerBlotTM used a single control and treated sample set, with 3 technical repeats that 
were compared in a 3x3 matrix. The subsequent validation experiments were also based 
on a single set of control and treated sample, and four technical repeats were performed 
to obtain a reasonable estimate of the mean fold change. For a protein with equal 
expression level in control and CADA-treated cells, the ratio of signals in control and 
CADA-treated cells will be 1. We employed a one-way ANOVA with Dunnett’s post hoc 
test to evaluate whether the log2-transformed ratios in our validation were significantly 
different from 1. To control the false positive rate of the entire family of comparisons, p-
values were adjusted to take into account that multiple comparison tests are conducted. 
The multiplicity adjusted p-value of a particular hypothesis is defined as the smallest 
significant level, when applied to the entire family of hypotheses, at which this particular 
hypothesis will be deemed statistically significant. The family-wise significance level was 
set to 5% for all experiments. All statistics were done in GraphPad Prism v7.0. 
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Results 
Use of the PowerBlotTM Western Array for proteomic analysis of CADA-treated 
SUP-T1 cells 
In an earlier study, we demonstrated how the small molecule CADA down-modulates 
hCD4 receptor expression by selective binding to the hCD4 pre-protein signal peptide 
with subsequent co-translational translocation inhibition (9). To further investigate the 
substrate selectivity of this drug, a proteomic study was set up in the human CD4+ T cell 
lymphoma SUP-T1. Cells were left untreated or were exposed to CADA for 72 h. The 
hCD4 down-modulating activity of CADA in our samples was verified by flow cytometry 
(Fig. 1B), before further downstream analysis with a PowerBlotTM Western Array (BD 
Biosciences).  
A panel of 1000 different monoclonal antibodies targeting a wide range of cellular 
signaling proteins was used in the array; 574 antibodies returned a detectable signal in 
the PowerBlot samples of SUP-T1 cells (Table S2), which mapped to 444 unique proteins 
(for several proteins multiple antibodies were used to identify different post-translational 
modifications). 
In the standard PowerBlot antibody panel, anti-hCD4 was not originally included. In order 
to detect our control protein, an anti-hCD4 antibody from BD (validated for flow cytometry 
only) was added to the antibody mixture. Unfortunately, the generalized multi-target 
western blot settings did not allow detection of hCD4 in the PowerBlot screening (Figure 
S1, last 2 lanes), even though flow cytometry data had confirmed the presence of hCD4 
in SUP-T1 cells and its down-modulation by CADA (Figure 1B). Protein samples in the 
PowerBlot assay were separated on a reducing SDS-PAGE, but non-reducing conditions 
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have been reported for immunoblotting of hCD4 (16, 17). As expected, hCD4 - which 
contains four immunoglobulin-like extracellular domains, three of them stabilized by 
disulfide-bridges (18) - could be clearly detected when non-reducing conditions were used 
for sample preparation and SDS-PAGE (Fig. 1C). Moreover, the western blot data show 
how CADA treatment results in a dose-dependent reduction of total hCD4 protein 
expression, which was identical to the flow cytometric analysis of cell surface hCD4 (Fig. 
1D). 
Analysis of the SUP-T1 PowerBlot suggests several potential CADA targets 
When all confidence levels were taken into account in the PowerBlot analysis, 54 of the 
574 detected antibody signals were down- or up-regulated by CADA treatment (Table S2 
and S3). We selected several candidate proteins for further analysis and validation. While 
a traditional approach would use an estimation of the amount of false positives and 
negatives in the dataset to select appropriate candidates, our target selection was 
primarily based on the BD’s confidence level (CL) classification parameters (see Table 
S1 for a description of the different confidence levels). Figure 2 shows a comparison 
between the BD PowerBlot candidates (from all 10 confidence levels) and a more 
common statistical analysis which uses the false discovery rate approach for candidate 
selection. The confidence level method used by BD mainly classified proteins located in 
the upper left and upper right portion of the graph (Fig. 2), which corresponds to the 
highest change in expression level and lowest risk for false positives. In addition, this 
classification also considers parameters such as low signal to reduce the amount of false 
positives in our candidate selection. 
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We selected the proteins with the highest confidence level for further validation with 
classical immunoblotting, because the expression level of these 9 potential CADA-
substrates was changed more than 2-fold in CADA-treated samples (Tables 1 and S2). 
This approach has also been used in several other PowerBlot studies (19-21). Individual 
immunoblots were optimized for the detection of each protein and we chose the 
abundantly expressed heavy chain of the structural protein clathrin as an internal control 
(predicted molecular weight of 192 kDa) that could be detected simultaneously with each 
selected target protein. Representative immunoblots of the 9 potential targets are given 
in Figure 3A. Surprisingly, almost none of the validation immunoblots could confirm a 
clear effect of CADA on the expression level of these nine proteins (Fig. 3A). 
Retinoblastoma-like protein 2 (pRb2) was the only protein with a significant change in 
expression (1.7-fold). This significant upregulation of pRb2 correlated well with the 
PowerBlot analysis (Table 1). 
As pRb2 is known to regulate G1/S cell cycle transition (22), we next evaluated whether 
CADA affects cell cycle progression by using propidium iodide staining of CADA-treated 
SUP-T1 cells and flow cytometry. The small molecule palbociclib is a selective inhibitor 
of cyclin dependent kinase 4 and 6 (Cdk4/D IC50 = 11 nM) (23), and was used as a control 
for G1/S arrest. Figure 3B shows how palbociclib causes a clear accumulation of SUP-
T1 cells in the G0/G1 phase and a reduction of the S and G2/M populations at 
concentrations ≥100 nM. CADA however, had no effect on the cell cycle distribution, as 
compared to the DMSO-treated control (Fig. 3B). 
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CADA additionally down-modulates an intracellular hCD4-related signaling protein 
To expand the selection of other candidate CADA-targets for further investigation, we 
next focused on hCD4-related proteins. hCD4 acts as a co-receptor for the T cell receptor 
(TCR)-CD3 complex on T-helper immune cells, which recognizes peptides presented on 
the major histocompatibility complex II. Lck (Leukocyte C-terminal Src kinase) is a T-cell 
specific protein tyrosine kinase which is constitutively associated with the cytoplasmic C-
terminus of CD4 and CD8 membrane proteins and acts in the TCR signaling cascade 
(24). The transcription factor c-Jun is part of the AP-1 activation complex and can be 
induced by the JNK pathway, which in turn can be activated through CD4 signaling (25). 
Despite the lower confidence level of Lck and c-Jun in the PowerBlot analysis (Table 1), 
we selected these candidate proteins for validation by optimized immunoblots. As shown 
in Figure 4A, we measured a significant decrease in the expression of hCD4 (8.2-fold), 
and c-Jun (1.9-fold). Cell cycle progression is also the main function of c-Jun, but as 
described above, cell cycle transition was not affected by CADA (Fig. 3B). 
As CADA-treatment reduces the amount of cell surface hCD4, it may have a potential 
impact on hCD4 receptor signaling in T cells. We therefore examined whether 
phosphorylation of several signaling components in the TCR signaling pathway of CD4-
positive T cells is affected by CADA. Activation of the TCR-CD3 complex triggers a 
signaling cascade, which is required for the in vivo proliferation and differentiation of T 
cells. Early signaling involves phosphorylation of the zeta-chain-associated protein kinase 
70 (ZAP-70). Tyr493 is phosphorylated by the activated TCR-CD3 complex and activates 
the enzymatic activity of ZAP-70. Importantly, the hCD4-associated tyrosine kinase Lck 
can phosphorylate Tyr319 in ZAP-70, which is also important for signaling (26). 
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Phosphorylated ZAP-70 will then activate downstream targets such as Linker for 
Activation of T cells (LAT), an essential protein in branching of the TCR signaling 
response (27).  
To verify TCR signaling in CADA treated cells, we stimulated T cells through antibody-
mediated cross-linking of the TCR-CD3 complex and then measured the phosphorylation 
state of ZAP-70 and LAT with western blot (Fig. 4B). Although described as a very robust 
method for T cell activation, the amount of phosphorylated ZAP-70 and LAT was not 
increased in stimulated SUP-T1 cells. We therefore performed an analog experiment with 
Jurkat cells, a T cell line which has been used extensively in TCR signaling research (28). 
As shown in Fig. 4B, antibody-mediated stimulation of Jurkat cells causes strong 
phosphorylation of the signaling proteins, which was similar in CADA-treated cells.  
CADA inhibits the co-translational translocation of sortilin into the ER lumen 
Finally, as CADA inhibits the co-translational translocation of hCD4 (9), we searched for 
other proteins that utilize the same ER-targeting pathway. We used bioinformatic 
prediction tools and the reviewed UniProtKB annotation of the antibody targets to 
determine that 5 of the proteins detected in the PowerBlot contained a non-cleavable 
signal anchor sequence (SAS) and 22 proteins contained a signal peptide (SP) (Table 
S4). Three of these SP-carrying proteins were classified by PowerBlot as differentially 
expressed: sortilin, cathepsin D and semaphorin-4D. However, sortilin was the only 
protein that passed visual inspection of the PowerBlot antibody signal and was allocated 
CL 7 (Table S3). Furthermore, sortilin was also down-modulated by CADA, whereas for 
cathepsin D and semaphorin-4D an up-regulation was observed. As evidenced by 
optimized immunoblots for sortilin (Table 1), we validated this protein as a significantly 
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down-modulated target of CADA (3.8-fold). However, the down-modulating effect of 
CADA on sortilin was only half of that on hCD4. 
Next, we determined whether both sortilin and hCD4 receptors are comparable substrates 
of our compound. Sortilin, also known as neurotensin receptor 3, shuttles between the 
cell surface and various organelles but is mainly expressed on the membranes of 
intracellular compartments such as the ER, Golgi and endosomes. It is a sorting receptor 
that is involved in protein sorting and targeting of ligands towards endosomes and 
lysosomes (29, 30). Because no monoclonal antibodies were available for intracellular 
detection of sortilin by flow cytometry, we obtained a plasmid encoding for GFP-fused 
sortilin so that sortilin expression could be determined by fluorescence of its GFP tag. To 
compare sortilin with hCD4 levels, HEK293T cells were co-transfected with sortilin-GFP 
and wild-type hCD4 encoding plasmids, and expression of both proteins was detected 
simultaneously with flow cytometry. As shown in Figure 5A, CADA down-modulated 
sortilin by about 50% but had a much stronger impact on hCD4 levels. Similar down-
modulation of sortilin by CADA was also observed when cells were transfected with 
sortilin-GFP alone (data not shown), excluding competition between the two substrates. 
Accordingly, immunoblotting of CADA treated SUP-T1 samples for sortilin revealed a 
dose-response effect of CADA on the protein level of wild-type sortilin (Fig. 5B). Similar 
results were obtained with another sortilin antibody (data not shown). 
Finally, to address whether CADA also down-modulates sortilin in a signal peptide-
dependent way, we tested the impact of CADA on protein translocation in a cell free in 
vitro translation system similar to that used in an earlier study on hCD4 (9). The signal 
peptide of sortilin was fused to the mature protein of bovine preprolactin (pPL) as outlined 
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in Figure 5C. Wild-type pPL and a hCD4-PL chimaera were included as controls. Whereas 
CADA had little impact on the translocation of wild-type pPL, it partially prevented the 
translocation of PL when this protein contained the SP of sortilin (Fig. 5C, about 50% 
inhibition at 15 µM CADA). This indicates that the observed susceptibility of sortilin to 
CADA resides in its N-terminal SP. Moreover, exchanging the SP of pPL for the N-
terminal SP-containing region of hCD4 rendered PL fully susceptible to the translocation 
inhibitory effect of CADA (Fig. 5C, 87% inhibition at 15 µM CADA). 
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Discussion 
In this study, we investigated whether there are additional substrates for the small 
molecule CADA besides hCD4. Only a limited selection of surface receptors was 
evaluated in previous work (2, 9), and we have now used Western array immunoblotting 
technology to perform a proteomic survey. Our current screen in the human CD4+ T cell 
lymphoma SUP-T1 was based on a panel of 1000 monoclonal antibodies covering the 
whole spectrum of intracellular pathways and categories related to cell division, cell 
signaling, transcription, translation, etc. This assay initially classified 12% of the 
detectable proteome as being differentially expressed in CADA-treated cells, but at 
varying ‘confidence levels’ ranging from as little as 1.25-fold change up to greater than 2-
fold difference. We selected several candidate proteins based upon BD classification and 
a priori knowledge from literature, for validation with classical immunoblots, flow 
cytometry and cell-free in vitro translocation. 
Comparison between the PowerBlot analysis and the optimized validation immunoblots 
led us to conclude that use of the general multi-target PowerBlot array results in an 
elevated false-positive rate. In the PowerBlot method, single samples are probed 
simultaneously with multiple antibodies and identification of differentially migrating (and 
sometimes partially degraded) proteins based on expected molecular weight can 
therefore lead to misidentification and masking of signals through non-specific 
interactions (for an example, see Fig. S1). The use of a single set of blotting conditions is 
also a compromise which may not allow successful detection of certain proteins in all 
sample types. For several of the PowerBlot hits, the difference between treated and 
untreated sample was classified as > 2-fold and was most likely over-estimated, 
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considering that no actual ratio could be calculated because of lack of signal in one of the 
matching samples (indicated with “n.v.” in Table 1). Nevertheless, the high-throughput 
immunoblotting PowerBlot screen is a well suited proteomic technique not only to rapidly 
identify new targets for a drug, but also to easily confirm potential hits since the PowerBlot 
antibodies are specified in the analysis and commercially available. 
Our PowerBlot data indicated that some factors involved in cell cycle progression such 
as pRb2 (22), Cyclin D3 (31) and c-Jun (25) are differentially expressed in CADA-treated 
cells. However, further analysis ruled out any inhibitory effect of CADA on cell cycle 
transition. These data are in line with previous observations that CADA has no anti-
proliferative effect on SUP-T1 cells. Cellular viability was not compromised by CADA and 
long-term CADA-treatment of T-cells was achieved, with preservation of hCD4 re-
expression following workout (9). Lowering the amount of cell surface hCD4 by CADA-
treatment did not affect activation of the T cell receptor signaling pathway, probably 
because hCD4 is mainly important in the enhancement of T cell sensitivity to antigens 
(32, 33). 
We have previously shown that the small molecule CADA down-modulates hCD4 surface 
expression by binding selectively to the hCD4 signal peptide, which inhibits the co-
translational translocation of hCD4 through the Sec61 channel (the translocon) (9). We 
therefore investigated whether other candidates of the PowerBlot proteome that contain 
a SP or SAS were affected by CADA and confirmed that the ER-targeted protein sortilin 
was significantly down-modulated by CADA. Sortilin, also known as neurotensin receptor 
3, is a 95 kDa type 1 transmembrane protein that belongs to the vacuolar protein sorting 
10 protein domain receptor family. It is expressed in various cell types, (29) and 
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intracellular sortilin is involved in protein sorting and targeting of ligands towards 
endosomes and lysosomes (30). Since both sortilin and hCD4 (which are down-
modulated by CADA) depend on the ER secretory pathway for their cellular expression, 
future proteomic analysis should focus on the secretome and the plasma membrane 
fraction in order to fully examine the range of compound substrates. Although the list of 
detected secretory and membrane proteins was limited in our current study, the 
identification of only one additional CADA-substrate suggests that the compound may not 
induce a wide-ranging and global block on ER translocation. 
Only a few other inhibitors of Sec61-mediated co-translational translocation have been 
reported to date [for an overview, see the review by Kalies and Römisch (34)]. Most of 
these inhibitors interfere with a specific step in the translocation process, and thus affect 
a wide spectrum of translocon substrates, often associated with cellular toxicity (35, 36). 
The fungal cyclic heptadepsipeptide HUN-7293 was originally identified as an inhibitor of 
VCAM-1 expression in endothelial cells (37, 38). Derivatives of this compound also act in 
a SP-dependent way, similar to CADA, but the precise mechanism of action and binding 
sites are likely different. The chemical structures show large differences and they affect 
the translocation of different target proteins. The derivative CAM741 inhibits the 
translocation of VCAM-1 and VEGF in a signal peptide-dependent way and interferes with 
the correct insertion of the VCAM-1 SP in the translocon (39-41). Another HUN-7293 
derivative is cotransin, which inhibits the translocation of several secretory and membrane 
proteins in a signal peptide-dependent manner (42). It is suggested that cotransin binds 
to the Sec61 plug domain, near the lateral gate of the translocon channel, which prevents 
the inserted protein from reaching the lumen of the ER (43, 44), and may explain its broad 
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substrate range. The selectivity of cotransin was recently addressed in a proteomic study 
(45), which revealed that the translocation of almost all secreted proteins was affected 
under saturating cotransin concentrations. However, the majority of integral membrane 
proteins were resistant to cotransin activity. Of note is that sortilin was identified in the 
limited list of cotransin-affected integral membrane proteins. It is known that translocating 
nascent proteins with different primary sequences place different demands on the 
transport machinery (46) and it seems that the conditions for the translocation of sortilin 
can be easily perturbed by different classes of small molecules that act within the ER 
translocon. 
Our previous studies indicated that CADA inhibits passage of nascent hCD4 through the 
translocon by blocking reorientation of the SP within the channel (9). CADA binds directly 
to the hCD4 SP, apparently forming a discrete complex that is stabilized by electrostatic 
and other interactions between the drug and its target (47). Our working hypothesis is that 
CADA stabilizes an otherwise transitory folded conformation of the SP within the channel. 
As seen in Figure 5A, translocation of hCD4 is not completely inhibited and the maximum 
down-modulation at high drug concentration is 87%. The IC50 value (concentration that 
produces 50% of total down-modulation) is 0.24 µM. Since the maximum effect of the 
compound on hCD4 is nearly 100%, this “absolute” IC50 value is almost the same as the 
“relative” IC50 value (0.21 µM), which is the concentration that produces 50% of maximal 
down-modulation (48). CADA is a much weaker inhibitor of sortilin translocation 
compared to hCD4. Figure 5A shows that the maximal down-modulation of sortilin 
measured by flow cytometry is only about 50%, which is consistent with the results 
obtained through different techniques. According to our mechanistic hypothesis, CADA 
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may also bind the sortilin SP in a folded conformation, but this complex less effectively 
inhibits protein translocation. The relative IC50 value (concentration that produces ca. 25% 
down-modulation of sortilin) of 0.38 µM shows that the CADA-sortilin SP complex is 
almost as stable as the CADA-hCD4 SP complex, since this corresponds to the inflection 
point on the dose-response curve and to the dissociation constant, assuming that the 
complex has 1:1 stoichiometry. Further work with different SP mutants will help to identify 
which specific residues interact with CADA, and refine our structural model for the SP-
small molecule complex within the translocon. Ideally, identifying a primary sequence 
consensus motif in the SP required for CADA sensitivity would be a big step forward in 
understanding the molecular mechanism of action and the selectivity of CADA towards 
target SPs. 
In conclusion, the present study suggested that CADA apparently has a low impact on 
the expression of almost 450 different cellular proteins. It also revealed that CADA inhibits 
sortilin translocation in a SP-dependent way, but causes weaker down-modulation 
relative to hCD4. To further assess substrate selectivity future studies on CADA should 
focus on the Sec61 secretory pathway and analyze a larger subset of secreted and 
membrane proteins, for example with an unbiased technique such as stable isotope 
labeling with amino acids in cell culture (SILAC)-based mass spectrometry. So far, 
CADA’s high selectivity for hCD4 down-modulation bodes well for its potential use as an 
alternative to anti-hCD4 antibodies in the treatment of numerous autoimmune diseases 
(49-52). 
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Figure legends 
FIG. 1. CADA dose-dependently down-modulates surface hCD4 expression. A) 
Structure of cyclotriazadisulfonamide (CADA). B) Flow cytometric determination of the 
hCD4 surface expression on SUP-T1 cells after 72 h treatment with 16 µM CADA, to 
verify hCD4 down-modulation by CADA in the samples subjected to PowerBlotTM 
analysis. Dotted line: unstained control; black: untreated control; grey: CADA. C) After 72 
h treatment of SUP-T1 cells with CADA, hCD4 was detected with western blot under non-
reducing conditions. One representative blot out of 4 is shown. D) Flow cytometric 
analysis of the hCD4 surface expression level before lysis (left axis, solid line, mean ± 
SEM, n = 5, absolute IC50 = 0.63 µM). Total hCD4 protein levels from the immunoblots in 
(C) were quantified and normalized to the clathrin control (right axis, dotted line, mean ± 
SEM, n = 4, absolute IC50 = 0.71 µM). Absolute IC50: CADA concentration that reduces 
the hCD4 expression to 50% of the untreated control. 
 
FIG. 2. PowerBlot Confidence Level-based substrate classification is in accordance 
with False Discovery Rate target selection. 574 signals were successfully mapped to 
the list of BD PowerBlot antibodies and the normalized fold changes (mean of 9 replicate 
measurements for each antibody, see methods) were log2 transformed for further 
analysis. P-values were calculated for each set of antibody signals, using an unpaired t 
test without assuming a consistent SD. We used the false discovery rate approach to 
adjust the p-values for multiple comparison testing (two-stage linear step-up procedure 
of Benjamini, Krieger and Yekutieli, with Q = 1%), which resulted in 202 signals with an 
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adjusted p-value <0.01, this threshold is indicated in the volcano plot with a dotted 
horizontal line. PowerBlot confidence level-selected substrates are indicated in blue, 
whereas the targets validated by optimized immunoblots are represented in red. 
 
FIG. 3. Optimized immunoblot validation of BD PowerBlot CL10-assigned targets 
shows upregulated pRb2 levels with CADA but cell cycle progression is not 
affected.  A) DMSO and CADA-treated (10 µM, 72 h) SUP-T1 samples were blotted 
under reducing conditions. Selected proteins were detected with conditions optimized for 
each individual primary antibody and representative images are shown for each protein 
(left panel). The signal intensity of the detected proteins in 4 independent immunoblot 
experiments were quantified and normalized to the clathrin internal control. The ratio 
between CADA and control (DMSO) signals for each protein is displayed as a Log2 value 
(right panel). The threshold for 2-fold change (Log2 ± 1.0), employed in the BD PowerBlot, 
is indicated with dotted lines. Star indicates significantly different from untreated control 
according to 1-way ANOVA using Dunnett’s post hoc test and a family-wise significance 
level of 5%. B) SUP-T1 cells were grown in the presence of DMSO, CADA or palbociclib 
for 48 hours before staining with propidium iodide and analysis of the cell cycle transition 
by flow cytometry. Bars in the graph represent mean values, n = 3. 
 
FIG. 4. CADA down-modulates hCD4 and c-Jun but does not affect phosphorylation 
events involved in early TCR signaling. A) DMSO and CADA-treated (10 µM, 72 h) 
SUP-T1 samples were blotted under non-reducing (left) and reducing conditions (right). 
35 
 
Selected proteins were identified with conditions optimized for each individual primary 
antibody and representative images are shown for each protein. Quantification was 
performed as in Figure 3A. B) SUP-T1 and Jurkat cells were grown in the presence of 
DMSO or CADA (10 µM) for 24 hours. Phosphorylation of TCR signaling proteins was 
then induced through cross-linking of CD3, followed by cell lysis and Western blotting (left 
panel; one representative set of blots out of 2 experiments is shown). Flow cytometric 
quantification of surface hCD4 levels on these cells shows that the down-modulation of 
hCD4 by 24h CADA-treatment was comparable between SUP-T1 and Jurkat cells, 
independent of activation by crosslinking CD3 (right panel; bars are mean ± SEM, n = 2). 
 
FIG. 5. CADA partially down-modulates sortilin expression in a signal peptide-
dependent way. A) HEK293T cells were co-transfected with human sortilin-GFP and 
human wild-type CD4, and were treated with the indicated amounts of CADA or 0.1% 
DMSO as a control. Sortilin and hCD4 expression were measured 48 h after transfection 
with flow cytometry (absolute IC50 values were 5.90 µM and 0.24 µM, respectively). Dotted 
line: sortilin-GFP; solid line: hCD4; mean ± SEM, n = 3. B) After 72 h treatment of SUP-
T1 cells with CADA, cells were lysed and sortilin was detected with western blot under 
non-reducing conditions. Detection was done with a rabbit antibody against human sortilin 
(clone EPR15010). C) Top panel shows the N-terminal amino acid sequence of bovine 
preprolactin (pPL) and two signal peptide chimaera. The signal peptide of pPL 
(underlined, grey) was replaced with the sortilin or hCD4 signal peptide (black) for use in 
radiolabeled cell-free in vitro translation reactions. Bottom left panel shows representative 
autoradiogram of the in vitro translated and translocated pPL variants. In the presence of 
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microsomes (RM), the preprotein (open arrowhead) is translocated into the ER lumen and 
the signal peptide is cleaved off, resulting in a faster migrating mature protein (black 
arrowhead) that is protected inside RM vesicles and thus protease K (PK) resistant. Signal 
intensities of the translocated protein fraction (black arrowhead) in protease K treated 
samples are shown in the bottom right graph. Bars are mean ± SEM; n ≥ 3. 
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TABLE 1. Potential CADA-affected PowerBlot targets selected for validation 
Uniprot ID Protein Function CLa Fold change PBb Fold change WBd 
Q9ULH1 
ASAP1 (Arf-GAP with SH3 
domain, ANK repeat and PH 
domain-containing protein 1) 
Regulates ADP-ribosylation factor 1 GTPase activity 10 - n.v. c 1.1 
Q15283 GAP1m (Ras GTPase-activating protein 2) 
Inhibitory regulator of Ras cAMP signaling 
Binds inositol tetrakisphosphate (IP4)  10 - n.v. 1.3 
P63208 p19 skp1 (S-phase kinase-associated protein 1) Component of the SCF ubiquitin ligase complex 10 - n.v. 1.1 
P42224 STAT1 (Signal transducer and activator of transcription 1) 
Signal transducer and transcription activator for 
interferon and cytokine signaling 10 -5.5 1.2 
P35637 FUS (RNA-binding protein FUS) Binds DNA, may act as a transcription activator  10 -3.2 -1.2 
Q13426 XRCC4 (DNA repair protein XRCC4) Involved in non-homologous end joining DNA repair 10 - n.v. 1.2 
P30281 Cyclin D3 (G1/S-specific cyclin-D3) Regulates cell cycle progression 10 5.7 1.2 
Q13501 Sequestome-1 (p62 Lck ligand) Phosphotyrosine-independent ligand for the Lck SH2 domain 10 2.4 1.1 
Q08999 pRb2 (Retinoblastoma-like protein 2) Regulates cell cycle progression 10 3.1 1.7* 
      
P05412 c-Jun (Transcription factor AP-1) Transcription factor, binds AP-1 and CRE-like sites 9 -2.0 -1.9* 
Q99523 Sortilin (Neurotensin receptor 3) Sorting receptor in the Golgi compartment 7 -2.1 -3.8* 
P06239 p56 Lck (Tyrosine-protein kinase Lck) 
CD4/CD8 associated signal transducer for T-cell 
antigen receptor 3 -2.1 1.2 
P01730 CD4 (cluster of differentiation 4) MHC class-II antigen/TCR co-receptor n.v. n.v. -8.2* 
a Confidence Level: assigned using signal criteria listed in Table S1. 
b Mean fold change of the 9 comparisons between DMSO and CADA samples in a 3x3 matrix as explained in Materials and Methods. 
c n.v. = no value. See the results section for details on CD4 detection in the PowerBlot system. Presence versus absence of a protein: fold change is not calculable. 
When no signal could be detected in the CADA (or DMSO) sample, but sufficient signal in the corresponding DMSO (or CADA) sample, the difference was classified as 
> 2-fold, although no actual ratio could be calculated (number/0). 
d Mean fold change in 4 classical western blots, numbers significantly different from 1 are indicated with (*).
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